Combination of tamsulosin and tolterodine alleviates refractory lower urinary tract symptoms in male patients.
- Author:
Yuan-ming SUN
1
;
Wei-dong GU
;
Jian-wei LÜ
;
Jing LENG
;
Juan-jie BO
;
Dong-ming LIU
Author Information
- Publication Type:Journal Article
- MeSH: Adrenergic alpha-1 Receptor Antagonists; therapeutic use; Aged; Aged, 80 and over; Benzhydryl Compounds; therapeutic use; Cresols; therapeutic use; Humans; Male; Middle Aged; Muscarinic Antagonists; therapeutic use; Phenylpropanolamine; therapeutic use; Prostatic Hyperplasia; drug therapy; Sulfonamides; therapeutic use; Tolterodine Tartrate; Treatment Outcome
- From: National Journal of Andrology 2010;16(9):790-793
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate and compare the clinical efficacy and safety of the highly selective alpha receptor antagonist tamsulosin and its combination with the M receptor antagonist tolterodine in the treatment of refractory lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH).
METHODSWe included in this study 184 BPH patients with refractory LUTS with the disease course of 4 weeks to 2 years, whose LUTS were not alleviated after a week's treatment with tamsulosin. The patients were randomly divided into Groups A and B, the former (n=89) treated with tamsulosin at 0.2 mg qd and the latter (n=95) given tolterodine at 2 mg bid in addition to tamsulosin medication, both for 4 weeks. Scores on IPSS, QOL and Qmax were obtained before and after the treatment, and the improvement of LUTS evaluated after the medication.
RESULTSThe tamsulosin group showed no significant differences before and after the treatment in the scores on IPSS (13.23 +/- 4.39 vs. 12.21 +/- 4.07), QOL (4.23 +/- 1.27 vs 3.53 +/- 0.95) and Qmax ([12.3 +/- 8.39] ml/s vs. [14.1 +/- 8.62] mls) (P > 0.05), while the combination group exhibited significantly higher scores on IPSS and QOL and lower score on Qmax after the medication than before it (IPSS: 14.45 +/- 5.31 vs. 6.56 +/- 2.03, P < 0.05; QOL: 4.45 +/- 0.79 vs. 2.34 +/- 0.73, P < 0.05; Qmax: [11.4 +/- 9.21] ml/s vs. [15.5 +/- 8.35] ml/s, P < 0.01). No severe complications were found in any of the cases.
CONCLUSIONCombination of tamsulosin and tolterodine can significantly alleviate refractory LUTS and improve QOL without causing serious adverse events in BPH patients.